Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Humanized immune system mouse models: progress, challenges and opportunities.

Allen TM, Brehm MA, Bridges S, Ferguson S, Kumar P, Mirochnitchenko O, Palucka K, Pelanda R, Sanders-Beer B, Shultz LD, Su L, PrabhuDas M.

Nat Immunol. 2019 Jun 3. doi: 10.1038/s41590-019-0416-z. [Epub ahead of print] No abstract available.

PMID:
31160798
2.

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 May 22;7(1):131. doi: 10.1186/s40425-019-0602-4. Review.

3.

Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals.

Thiébaut R, Hejblum BP, Hocini H, Bonnabau H, Skinner J, Montes M, Lacabaratz C, Richert L, Palucka K, Banchereau J, Lévy Y.

Front Immunol. 2019 Apr 24;10:874. doi: 10.3389/fimmu.2019.00874. eCollection 2019.

4.

Evaluation of the health behaviors of women in multiple pregnancies - a preliminary study.

Pilewska-Kozak AB, Dobrowolska BB, Tkaczuk-Włach J, Stadnicka G, Łepecka-Klusek C, Pałucka K, Ziółkowska M.

Ginekol Pol. 2018;89(6):289-294. doi: 10.5603/GP.a2018.0050.

5.

Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.

Wang M, Yao LC, Cheng M, Cai D, Martinek J, Pan CX, Shi W, Ma AH, De Vere White RW, Airhart S, Liu ET, Banchereau J, Brehm MA, Greiner DL, Shultz LD, Palucka K, Keck JG.

FASEB J. 2018 Mar;32(3):1537-1549. doi: 10.1096/fj.201700740R. Epub 2018 Jan 3.

6.

A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis.

Cepika AM, Banchereau R, Segura E, Ohouo M, Cantarel B, Goller K, Cantrell V, Ruchaud E, Gatewood E, Nguyen P, Gu J, Anguiano E, Zurawski S, Baisch JM, Punaro M, Baldwin N, Obermoser G, Palucka K, Banchereau J, Amigorena S, Pascual V.

J Exp Med. 2017 Nov 6;214(11):3449-3466. doi: 10.1084/jem.20170412. Epub 2017 Sep 21.

7.

Immunotherapy: Cancer vaccines on the move.

Banchereau J, Palucka K.

Nat Rev Clin Oncol. 2018 Jan;15(1):9-10. doi: 10.1038/nrclinonc.2017.149. Epub 2017 Sep 12. No abstract available.

PMID:
28895570
8.

Influenza vaccines differentially regulate the interferon response in human dendritic cell subsets.

Athale S, Banchereau R, Thompson-Snipes L, Wang Y, Palucka K, Pascual V, Banchereau J.

Sci Transl Med. 2017 Mar 22;9(382). pii: eaaf9194. doi: 10.1126/scitranslmed.aaf9194.

9.

Diversity and collaboration for effective immunotherapy.

Palucka K, Banchereau J.

Nat Med. 2016 Dec 6;22(12):1390-1391. doi: 10.1038/nm.4249. No abstract available.

PMID:
27923023
10.

Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus.

Caielli S, Athale S, Domic B, Murat E, Chandra M, Banchereau R, Baisch J, Phelps K, Clayton S, Gong M, Wright T, Punaro M, Palucka K, Guiducci C, Banchereau J, Pascual V.

J Exp Med. 2016 May 2;213(5):697-713. doi: 10.1084/jem.20151876. Epub 2016 Apr 18.

11.

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.

Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN).

J Immunother Cancer. 2016 Mar 15;4:15. doi: 10.1186/s40425-016-0118-0. eCollection 2016. Review.

12.

Standardizing Flow Cytometry Immunophenotyping Analysis from the Human ImmunoPhenotyping Consortium.

Finak G, Langweiler M, Jaimes M, Malek M, Taghiyar J, Korin Y, Raddassi K, Devine L, Obermoser G, Pekalski ML, Pontikos N, Diaz A, Heck S, Villanova F, Terrazzini N, Kern F, Qian Y, Stanton R, Wang K, Brandes A, Ramey J, Aghaeepour N, Mosmann T, Scheuermann RH, Reed E, Palucka K, Pascual V, Blomberg BB, Nestle F, Nussenblatt RB, Brinkman RR, Gottardo R, Maecker H, McCoy JP.

Sci Rep. 2016 Feb 10;6:20686. doi: 10.1038/srep20686.

13.

Immunotherapy: The path to win the war on cancer?

Topalian SL, Wolchok JD, Chan TA, Mellman I, Palucka K, Banchereau J, Rosenberg SA, Dane Wittrup K.

Cell. 2015 Apr 9;161(2):185-6. No abstract available.

14.

Decreased HIV-specific T-regulatory responses are associated with effective DC-vaccine induced immunity.

Brezar V, Ruffin N, Richert L, Surenaud M, Lacabaratz C, Palucka K, Thiébaut R, Banchereau J, Levy Y, Seddiki N.

PLoS Pathog. 2015 Mar 27;11(3):e1004752. doi: 10.1371/journal.ppat.1004752. eCollection 2015 Mar.

15.

Transcriptional specialization of human dendritic cell subsets in response to microbial vaccines.

Banchereau R, Baldwin N, Cepika AM, Athale S, Xue Y, Yu CI, Metang P, Cheruku A, Berthier I, Gayet I, Wang Y, Ohouo M, Snipes L, Xu H, Obermoser G, Blankenship D, Oh S, Ramilo O, Chaussabel D, Banchereau J, Palucka K, Pascual V.

Nat Commun. 2014 Oct 22;5:5283. doi: 10.1038/ncomms6283.

16.

Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load.

Lévy Y, Thiébaut R, Montes M, Lacabaratz C, Sloan L, King B, Pérusat S, Harrod C, Cobb A, Roberts LK, Surenaud M, Boucherie C, Zurawski S, Delaugerre C, Richert L, Chêne G, Banchereau J, Palucka K.

Eur J Immunol. 2014 Sep;44(9):2802-10. doi: 10.1002/eji.201344433.

17.

Reprogramming tumor-infiltrating dendritic cells for CD103+ CD8+ mucosal T-cell differentiation and breast cancer rejection.

Wu TC, Xu K, Banchereau R, Marches F, Yu CI, Martinek J, Anguiano E, Pedroza-Gonzalez A, Snipes GJ, O'Shaughnessy J, Nishimura S, Liu YJ, Pascual V, Banchereau J, Oh S, Palucka K.

Cancer Immunol Res. 2014 May;2(5):487-500. doi: 10.1158/2326-6066.CIR-13-0217. Epub 2014 Mar 4.

18.

SnapShot: cancer vaccines.

Palucka K, Banchereau J.

Cell. 2014 Apr 10;157(2):516-516.e1. doi: 10.1016/j.cell.2014.03.044.

19.

Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease.

Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG, Moskalenko MM, Sivendran M, Fu Y, de Moll EH, Pan M, Moon JY, Arora S, Cohain A, DiFeo A, Ferringer TC, Tismenetsky M, Tsui CL, Friedlander PA, Parides MK, Banchereau J, Chaussabel D, Lebwohl MG, Wolchok JD, Bhardwaj N, Burakoff SJ, Oh WK, Palucka K, Merad M, Schadt EE, Saenger YM.

J Invest Dermatol. 2014 Aug;134(8):2202-2211. doi: 10.1038/jid.2014.85. Epub 2014 Feb 12.

20.

Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children.

Cao RG, Suarez NM, Obermoser G, Lopez SM, Flano E, Mertz SE, Albrecht RA, García-Sastre A, Mejias A, Xu H, Qin H, Blankenship D, Palucka K, Pascual V, Ramilo O.

J Infect Dis. 2014 Jul 15;210(2):224-33. doi: 10.1093/infdis/jiu079. Epub 2014 Feb 4.

21.

Q&A: Evidence presenter. Interview by Marian Turner.

Palucka K.

Nature. 2013 Dec 19;504(7480):S9. doi: 10.1038/504S9a. No abstract available.

PMID:
24352364
22.

Dendritic cells, inflammation, and breast cancer.

Palucka K, Coussens LM, O'Shaughnessy J.

Cancer J. 2013 Nov-Dec;19(6):511-6. doi: 10.1097/PPO.0000000000000007. Review.

23.

Evaluation of cancer immunity in mice.

Disis ML, Palucka K.

Cold Spring Harb Protoc. 2014 Mar 1;2014(3):231-4. doi: 10.1101/pdb.top078816.

24.

Dendritic-cell-based therapeutic cancer vaccines.

Palucka K, Banchereau J.

Immunity. 2013 Jul 25;39(1):38-48. doi: 10.1016/j.immuni.2013.07.004. Review.

25.

Human dendritic cell subsets in vaccination.

Palucka K, Banchereau J.

Curr Opin Immunol. 2013 Jun;25(3):396-402. doi: 10.1016/j.coi.2013.05.001. Epub 2013 May 30. Review.

26.

Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines.

Obermoser G, Presnell S, Domico K, Xu H, Wang Y, Anguiano E, Thompson-Snipes L, Ranganathan R, Zeitner B, Bjork A, Anderson D, Speake C, Ruchaud E, Skinner J, Alsina L, Sharma M, Dutartre H, Cepika A, Israelsson E, Nguyen P, Nguyen QA, Harrod AC, Zurawski SM, Pascual V, Ueno H, Nepom GT, Quinn C, Blankenship D, Palucka K, Banchereau J, Chaussabel D.

Immunity. 2013 Apr 18;38(4):831-44. doi: 10.1016/j.immuni.2012.12.008.

27.

Human CD1c+ dendritic cells drive the differentiation of CD103+ CD8+ mucosal effector T cells via the cytokine TGF-β.

Yu CI, Becker C, Wang Y, Marches F, Helft J, Leboeuf M, Anguiano E, Pourpe S, Goller K, Pascual V, Banchereau J, Merad M, Palucka K.

Immunity. 2013 Apr 18;38(4):818-30. doi: 10.1016/j.immuni.2013.03.004. Epub 2013 Apr 4.

28.

H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice.

Margine I, Hai R, Albrecht RA, Obermoser G, Harrod AC, Banchereau J, Palucka K, García-Sastre A, Palese P, Treanor JJ, Krammer F.

J Virol. 2013 Apr;87(8):4728-37. doi: 10.1128/JVI.03509-12. Epub 2013 Feb 13.

29.

Immunoglobulin-like transcript receptors on human dermal CD14+ dendritic cells act as a CD8-antagonist to control cytotoxic T cell priming.

Banchereau J, Zurawski S, Thompson-Snipes L, Blanck JP, Clayton S, Munk A, Cao Y, Wang Z, Khandelwal S, Hu J, McCoy WH 4th, Palucka KA, Reiter Y, Fremont DH, Zurawski G, Colonna M, Shaw AS, Klechevsky E.

Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18885-90. doi: 10.1073/pnas.1205785109. Epub 2012 Oct 29.

30.

Cancer immunotherapy via dendritic cells.

Palucka K, Banchereau J.

Nat Rev Cancer. 2012 Mar 22;12(4):265-77. doi: 10.1038/nrc3258. Review.

31.

Antibody co-targeting of DCs.

Zitvogel L, Palucka K.

Blood. 2011 Dec 22;118(26):6726-7. doi: 10.1182/blood-2011-10-384552. No abstract available.

32.

Targeting human dendritic cell subsets for improved vaccines.

Ueno H, Klechevsky E, Schmitt N, Ni L, Flamar AL, Zurawski S, Zurawski G, Palucka K, Banchereau J, Oh S.

Semin Immunol. 2011 Feb;23(1):21-7. doi: 10.1016/j.smim.2011.01.004. Epub 2011 Jan 28. Review.

33.

Recent developments in cancer vaccines.

Palucka K, Ueno H, Banchereau J.

J Immunol. 2011 Feb 1;186(3):1325-31. doi: 10.4049/jimmunol.0902539. Review.

34.

Dendritic cells and immunity against cancer.

Palucka K, Ueno H, Fay J, Banchereau J.

J Intern Med. 2011 Jan;269(1):64-73. doi: 10.1111/j.1365-2796.2010.02317.x. Review.

35.

Designing vaccines based on biology of human dendritic cell subsets.

Palucka K, Banchereau J, Mellman I.

Immunity. 2010 Oct 29;33(4):464-78. doi: 10.1016/j.immuni.2010.10.007. Review.

36.

Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes.

Wieckowski E, Chatta GS, Mailliard RM, Gooding W, Palucka K, Banchereau J, Kalinski P.

Prostate. 2011 Feb 1;71(2):125-33. doi: 10.1002/pros.21228. Epub 2010 Aug 17.

37.

Dendritic cells: are they clinically relevant?

Palucka K, Ueno H, Roberts L, Fay J, Banchereau J.

Cancer J. 2010 Jul-Aug;16(4):318-24. doi: 10.1097/PPO.0b013e3181eaca83. Review.

38.

Dendritic cell subsets as vectors and targets for improved cancer therapy.

Palucka K, Ueno H, Roberts L, Fay J, Banchereau J.

Curr Top Microbiol Immunol. 2011;344:173-92. doi: 10.1007/82_2010_48. Review.

39.

Understanding and activating immunity against human cancer.

Stevenson FK, Palucka K.

Curr Opin Immunol. 2010 Apr;22(2):212-4. doi: 10.1016/j.coi.2010.03.001. Epub 2010 Mar 24. No abstract available.

40.

Building on dendritic cell subsets to improve cancer vaccines.

Palucka K, Ueno H, Zurawski G, Fay J, Banchereau J.

Curr Opin Immunol. 2010 Apr;22(2):258-63. doi: 10.1016/j.coi.2010.02.010. Epub 2010 Mar 11. Review.

41.

Harnessing human dendritic cell subsets for medicine.

Ueno H, Schmitt N, Klechevsky E, Pedroza-Gonzalez A, Matsui T, Zurawski G, Oh S, Fay J, Pascual V, Banchereau J, Palucka K.

Immunol Rev. 2010 Mar;234(1):199-212. doi: 10.1111/j.0105-2896.2009.00884.x. Review.

42.

Harnessing dendritic cells to generate cancer vaccines.

Palucka K, Ueno H, Fay J, Banchereau J.

Ann N Y Acad Sci. 2009 Sep;1174:88-98. doi: 10.1111/j.1749-6632.2009.05000.x.

43.

Harnessing human dendritic cell subsets to design novel vaccines.

Banchereau J, Klechevsky E, Schmitt N, Morita R, Palucka K, Ueno H.

Ann N Y Acad Sci. 2009 Sep;1174:24-32. doi: 10.1111/j.1749-6632.2009.04999.x. Review.

44.

A T cell-dependent mechanism for the induction of human mucosal homing immunoglobulin A-secreting plasmablasts.

Dullaers M, Li D, Xue Y, Ni L, Gayet I, Morita R, Ueno H, Palucka KA, Banchereau J, Oh S.

Immunity. 2009 Jan 16;30(1):120-9. doi: 10.1016/j.immuni.2008.11.008.

45.

Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts.

Klechevsky E, Gallegos M, Denkberg G, Palucka K, Banchereau J, Cohen C, Reiter Y.

Cancer Res. 2008 Aug 1;68(15):6360-7. doi: 10.1158/0008-5472.CAN-08-0928.

46.

Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade.

Allantaz F, Chaussabel D, Stichweh D, Bennett L, Allman W, Mejias A, Ardura M, Chung W, Smith E, Wise C, Palucka K, Ramilo O, Punaro M, Banchereau J, Pascual V.

J Exp Med. 2007 Sep 3;204(9):2131-44. Epub 2007 Aug 27. Erratum in: J Exp Med. 2009 Sep 28;206(10):2299. Smith, Elisabeth [added].

47.

How dendritic cells and microbes interact to elicit or subvert protective immune responses.

Palucka K, Banchereau J.

Curr Opin Immunol. 2002 Aug;14(4):420-31. Review.

PMID:
12088675
48.

Expression of the signal transduction molecule zeta in peripheral and tumour-associated lymphocytes in Hodgkin's disease in relation to the Epstein-Barr virus status of the tumour cells.

Sjöberg J, Andersson M, Garcia C, Palucka KA, Björkholm M, Porwit-MacDonald A, Pisa P.

Br J Haematol. 2002 Mar;116(4):765-73.

PMID:
11886379
49.

Sensing pathogens and tuning immune responses.

Pulendran B, Palucka K, Banchereau J.

Science. 2001 Jul 13;293(5528):253-6. Review.

PMID:
11452116
50.

Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries?

Banchereau J, Pulendran B, Steinman R, Palucka K.

J Exp Med. 2000 Dec 18;192(12):F39-44. No abstract available.

Supplemental Content

Loading ...
Support Center